Last reviewed · How we verify

ANX007 — Competitive Intelligence Brief

ANX007 (ANX007) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-Aβ oligomer antibody. Area: Neurology.

phase 2 Anti-Aβ oligomer antibody Amyloid-beta oligomers Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ANX007 (ANX007) — Annexon, Inc.. ANX007 is an anti-Aβ oligomer antibody targeting the aggregation of amyloid-beta oligomers in the brain.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ANX007 TARGET ANX007 Annexon, Inc. phase 2 Anti-Aβ oligomer antibody Amyloid-beta oligomers

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-Aβ oligomer antibody class)

  1. Annexon, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ANX007 — Competitive Intelligence Brief. https://druglandscape.com/ci/anx007. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: